Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

Algernon has manipulated the prelim read out. fact. Changing the sample size at the last moment is NOT acceptable. It is data manipulation and unethical. The data safety monitoring board has nothing to do with them reporting their data, they only comment on the safety of the patients.

They found their primary outcome failed. They were scavenging for a secondary and had to manipulate the number in the analysis to try and find signal. This does suggest that the numbers from the final analysis will be weak.

Hence why im out.

VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report, in a descriptive format, positive trending interim data for the Phase 2b part of the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19.....[...] "While the Company originally advised that the interim data set would be based on 75 patients, this was increased to up to 123 patients for some of the endpoints owing to the availability of the data."

VANCOUVER, British Columbia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study.

The Company reports that due to a fire at the Romanian Hospital site, there was a delay in completing the site audit as planned.

VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has decided to review its protocol for its phase 2b/3 study of Ifenprodil for COVID-19, to consider adding lung scarring as an additional endpoint if sufficient data is available from a significant number of patients.

SEARCHING FOR ADDITIONAL ENDPOINTS
ADDING ENDPOINTS
MANIPULATING PREFORMED SAMPLE SIZE IN AN OPEN TRIAL